Based on the publication of the Q1 2021 Interim Report earlier the same day, the senior Management Team will offer a walkthrough of the report contents and answer pre-submitted questions from the audience.
At this presentation, the CEO will also present the investment case of the company as it is presented in the prospectus for the ongoing Rights Issue.
Pre-submitted questions will be prioritized. To submit a question, please send it to investorrelations@allarity.com, no later than 2:30 pm on 28 May.
Allarity Therapeutics is building a personalized medicine company developing new therapeutics for unmet needs in the treatment of human cancers through the use of the company's world-class predictive diagnostics platform.
Agenda
General and Operational Status by the CEO
Financials by the CFO
Rights Issue
Q&A
Price
Free
Language
English
OPEN TO
Anyone with the event link can attend
Dial-in Number
Please register for this Webinar to view the dial-in info.
CEO and Member of the Board of Directors, Allarity Therapeutics A/S
30+ years of commercial industry experience focused in oncology, including former CEO roles at Apexian Pharmaceuticals, Raphael Pharmaceuticals (formerly Cornerstone Pharmaceuticals), and Senior Vice President and President, Commercial Operations...
30+ years of experience as a Vice President of Finance and Controller in numerous public and private companies, including in the life sciences sector. Most recently, he served as VP of Finance & Operations at Metabo Corporation. Prior to that, he...